<code id='A57F7BCDDB'></code><style id='A57F7BCDDB'></style>
    • <acronym id='A57F7BCDDB'></acronym>
      <center id='A57F7BCDDB'><center id='A57F7BCDDB'><tfoot id='A57F7BCDDB'></tfoot></center><abbr id='A57F7BCDDB'><dir id='A57F7BCDDB'><tfoot id='A57F7BCDDB'></tfoot><noframes id='A57F7BCDDB'>

    • <optgroup id='A57F7BCDDB'><strike id='A57F7BCDDB'><sup id='A57F7BCDDB'></sup></strike><code id='A57F7BCDDB'></code></optgroup>
        1. <b id='A57F7BCDDB'><label id='A57F7BCDDB'><select id='A57F7BCDDB'><dt id='A57F7BCDDB'><span id='A57F7BCDDB'></span></dt></select></label></b><u id='A57F7BCDDB'></u>
          <i id='A57F7BCDDB'><strike id='A57F7BCDDB'><tt id='A57F7BCDDB'><pre id='A57F7BCDDB'></pre></tt></strike></i>

          Home / Wikipedia / explore

          explore


          explore

          author:leisure time    Page View:629
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In